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Background: Recent studies suggest that bacterial endotoxins may be associated with various chronic diseases,
including colorectal adenomas and cancer. Given the evidence linking inflammation and colorectal cancer, we
sought to determine if plasma endotoxin concentrations are associated with indicators of systemic or local
inflammation and colorectal adenomas.
Methods: This cross-sectional study consisted of participants who underwent screening colonoscopies and
included adenoma cases (n=138) and non-adenoma controls (n=324). Plasma concentrations of endotoxin were
measured with Limulus Amebocyte Lysate (LAL) assay. We quantified concentrations of inflammatory cytokines,
interleukin-4 (IL-4), IL-6, IL-8, IL-10, IL-12, tumor necrosis factor-alpha (TNF-α), and interferon-γ (IFN-γ) in plasma by
ELISA and mRNA expression levels in rectal mucosal biopsies by quantitative RT-PCR. Interleukin-17 was evaluated
only in the rectal mucosa.
Results: Compared to subjects with low plasma endotoxin concentrations, those with higher concentrations were
more likely to have adenomas (OR 1.4, 95% CI 1.0-2.1). Among subjects with adenomas, those with villous histology
were more likely to have higher endotoxin concentrations (5.4 vs. 4.1EU/mL, p=0.05) and lower plasma IFN-γ (0 vs.
1.64 pg/mL, p=0.02) compared to those with only tubular adenomas. Cases showed a trend of having higher
plasma TNF-α levels than controls (p=0.06), but none of the other plasma or rectal mucosal cytokine levels differed
between cases and controls. Elevated mucosal IL-12 levels were associated with having multiple adenomas
(p=0.04). Higher concentrations of plasma endotoxin predicted increased plasma IL-12 levels (OR 1.5, 95% CI 1.0-2.2)
and rectal mucosal IL-12 (OR 1.9, 95% CI 1.0-3.7) and IL-17 gene expression (OR 2.2, 95% CI 1.0-4.6).
Conclusions: These findings suggest that interactions between elevated plasma endotoxin concentrations and
inflammatory cytokines may be relevant to the development of colorectal adenomas.
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Colorectal cancer (CRC) is one of the leading causes of
cancer death in the world and the United States [1] with
the majority of cases having no previous family history.
Sporadic CRC has been linked to several risk factors in-
cluding accumulation of genetic mutations, inflamma-
tory states such as inflammatory bowel disease, and
environmental factors such as smoking and obesity.
More recently, CRC has been linked to changes in the
gut microbiota [2-5]. While bacterial dysbiosis has been* Correspondence: melissa_kang@med.unc.edu
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reproduction in any medium, provided the orassociated with CRC, the mechanism by which it
promotes colon carcinogenesis has not been elucidated.
As adenomas are known CRC precursors, studies to de-
termine risk factors for adenomas could be crucial to
prevention and treatment of CRC. Consequently, identi-
fying the role of gut bacteria, microbial products, and
their effect on inflammation can further aid in our
understanding of CRC pathogenesis.
The human intestine is a complex and unique environ-
ment inhabited by 1013 bacteria that interact with the in-
testinal mucosa to affect gut immunity and homeostasis
[6-9]. An imbalance of the bacterial population in favor
of pro-oncogenic bacteria could lead to abnormald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kang et al. BMC Cancer 2013, 13:91 Page 2 of 8
http://www.biomedcentral.com/1471-2407/13/91proliferation of the colonic epithelium and adenoma for-
mation [10,11]. Although previous studies have reported
an association between gram-positive bacteria, Strepto-
coccus gallolyticus (formerly S. bovis) and colorectal neo-
plasia [12], we have demonstrated that an increased
abundance of Proteobacteria, a decreased abundance of
Bacteroides, and a disproportionate colonization of the
gut with predominant Escherichia coli were associated
with adenomatous states [13,14]. More recently, Kostic
et al. observed that Fusobacterium were enriched in
CRC, also supporting a role of gram-negative bacteria in
colorectal carcinogenesis [2]. One of the proposed
mechanisms by which S. gallolyticus promotes develop-
ment of colorectal tumors is through the production of
inflammatory cytokines by the release of their cell wall
antigens [12]. Thus, bacterial dysbiosis that favors higher
abundance of gram-negative bacteria could contribute to
the formation of adenomas via increased endotoxin re-
lease and inflammation.
Endotoxin, or lipopolysaccharide (LPS), is a compo-
nent of the cell wall of gram negative bacteria and is
released into the host environment by the destruction of
the cell wall. Studies have shown that certain bacterial
types are correlated with elevated concentrations of
plasma endotoxin [15,16], which can have detrimental
effects. Under experimental conditions, endotoxin binds
to LPS-binding protein to form a complex with CD14,
which leads to activation of toll-like receptor 4 (TLR-4),
initiation of innate inflammatory response, activation
of macrophages and monocytes, and production of
pro-inflammatory cytokines such as tumor necrosis
factor-α (TNF-α), interleukin (IL)-6, and IL-23 [15-20].
An overabundance of LPS-rich bacteria in the gut may
provide an environment that is conducive for chronic in-
flammation and increased production of pro-inflammatory
cytokines and reactive oxygen species. These cytokines can
activate the NF-κβ pathway, which has been implicated
in cell proliferation and DNA damage leading to car-
cinogenesis [17-20].
The aim of our study was to determine the relation-
ship between plasma endotoxin, systemic and local in-
flammation, and colorectal adenomas. We assessed the
association between plasma endotoxin concentrations,
plasma cytokines IL-4, IL-6, IL-8, IL-10, TNF-α, and
interferon-γ (IFN-γ) levels, and local cytokine mRNA
expression levels of IL-4, IL-6, IL-8, IL-10, IL-17,
TNF-α, and IFN-γ in relation to adenomas.
Methods
Study population. The study population and data collec-
tion were as previously described [13,14]. The subjects
in this cross-sectional study were drawn from the Diet
and Healthy Study V (DHSV), where participants
underwent screening colonoscopies at the University ofNorth Carolina at Chapel Hill Hospitals. Eligibility
requirements were as follows: age ≥ 30 years; proficiency
in English to provide informed written consent and par-
ticipate in a phone interview; a satisfactory preparation for
colonoscopy and complete examination to the cecum;
outpatient; no history of familial polyposis, colitis, previ-
ous colonic resection, previous colon cancer or polyps;
and had not taken antibiotics within 12 weeks prior to the
colonoscopy. Information about diet and lifestyle was
collected by telephone interview for each subject within
12 weeks of the colonoscopy. Anthropometric measures
were obtained on the day of the colonoscopy. Rectal mu-
cosal biopsies taken at 10–12 cm from the anal verge were
obtained during colonoscopy. All participating subjects
provided written informed consents and consented to
blood samples. Subjects who had adenomatous polyps
at colonoscopy were classified as cases (n=138) and
subjects without adenomas as controls (n=324). The
study was approved by the Institutional Review Board
at the University of North Carolina, School of Medicine
(Protocol #05-3138).
Plasma endotoxin assay. Blood samples were collected
in EDTA-containing tubes, and plasma was separated by
centrifugation. Plasma samples were frozen in small
aliquots at −80°C to prevent repeated freezing and
thawing until analysis. Plasma endotoxin concentrations
were measured using a commercially available quantita-
tive chromogenic endpoint Limulus Amebocyte Lysate
(LAL) QCL-1000 kit (Lonza, Walkersville, MD). Briefly,
300 μl of plasma was diluted 1:3 with 10 mM MgCl2
(Lonza), then heat inactivated at 70°C for 30 min,
followed by further dilutions to 1:30–1:40 and 50 μl of
the diluted sample was added to a 96-well pyrogen-free
culture plate. Remaining procedures were performed
according to the manufacturer’s instructions. Endotoxin
concentrations (EU/ml) in the samples were determined
from a standard curve using pure endotoxin standards.
All assays were run in duplicate. The detection range of
this kit was 0.1EU/ml to 1.0EU/ml. For samples that
were below the lowest standard value, endotoxin con-
centration was calculated as the blank (negative control)
concentration value of 0.055 times the dilution factor.
Two samples required much larger dilutions at a ratio of
1:99 and could not be accurately compared to the endo-
toxin standard curve. These two samples were removed
as outliers. The intra-assay and inter-assay coefficients
were 4.3% and 17.2%, respectively.
Quality control for plasma endotoxin assay. Blood
samples were collected in EDTA-containing tubes to
prevent coagulation. Because LAL is composed of the
coagulation system of the horseshoe crab, EDTA can in-
hibit LAL gel formation by chelating divalent cations in
the LAL formulation, thus, depleting the lysate of the
cations it needs to function properly. Therefore, samples
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tory nature of EDTA. This method was proven to pass
the positive product control test by the manufacturer.
Furthermore, plasma contains protein components that
could inhibit the assay. To verify the lack of product in-
hibition, samples were tested for inhibition according to
the manufacturer’s instructions. Briefly, samples were
either spiked with 0.4 EU/mL of endotoxin or unspiked.
Endotoxin concentrations from both samples were
determined. If the difference between spiked and
unspiked samples equaled 0.4 EU/mL + 25%, the sample
was considered uninhibited. We performed this on
groups of samples and determined that plasma
containing hemolyzed red blood cells did not pass the
test. Thus, only plasma samples with clear yellow color
passed the test and were included in our assay. With
these measures, the components potentially interfering
with the reaction were minimized.
Enzyme-linked immunosorbent assay (ELISA) of plasma
cytokines. ELISA was used to quantify inflammatory
cytokines in the plasma samples. Any samples with gross
hemolysis or lipemia were not assayed. Plasma samples
were thawed and centrifuged to remove any precipitates
prior to running the assay. The plasma cytokine assay was
performed using the Milliplex high sensitivity human cyto-
kine kit for IL-4, IL-6, IL-8, IL-10, TNF-α, and IFN-γ
(HSCYTO-60SK, Millipore, Billerica, MA) following the
manufacturer’s recommendation. Plasma samples were
mixed with fluorescently labeled, color coded microspheres
in 96-well plates and incubated overnight at 4°C. The next
day plates were washed, and a biotinylated detection anti-
body was added, followed by incubation with agitation for
1 h at room temperature. Next, Streptavidin-Phycoerythrin
was added to each well, followed by incubation for 30 min
and another wash step. Finally, the reaction was read im-
mediately on the Bioplex 200 System (Biorad, Hercules
CA). Fluorescent intensities for the samples were derived
by fitting on a standard curve. Each assay was run in dupli-
cate with positive controls included in each batch. The
average of two measurements was used for data analysis.
Minimal detection levels were 0.13 pg/mL for IL-4,
0.10 pg/mL for IL-6, 0.11 pg/mL for IL-8, 0.15 pg/mL for
IL-10, 0.05 pg/mL for TNF-α, and 0.29 pg/mL for IFN-γ.
The intra-assay and inter-assay coefficients of variation
were 4.16% and 9.12% for IL-4, 3.51% and 4.48% for IL-6,
3.26% and 6.48% for IL-8, 3.31% and 11.84% for IL-10,
3.49% and 3.78% for TNF-α, and 4.88% and 7.79% for
IFN-γ respectively.
RNA extraction, reverse transcription and quantitative
real-time PCR (qRT-PCR) of rectal mucosal biopsies.
Rectal biopsies were placed in RNA Later (Qiagen,
Valencia, CA) immediately after collection. RNA extrac-
tion was performed within 1 week of obtaining the tissue
biopsies, and isolated RNA was stored at −80°C in smallaliquots to prevent repeated freezing and thawing.
Extraction of RNA and qRT-PCR were previously
described [21,22]. Briefly, RNA was extracted from tissue
biopsies using the Qiagen RNeasy Protect Mini Kit
following the manufacturer’s protocol (Qiagen, Valencia,
CA). RNA purity and concentration were evaluated by
Agilent Bioanalyzer (Agilent, Santa Clara, CA) as well as
absorbance readings using the NanoDrop ND-1000
spectrophotometer immediately after the extraction
(Thermo Scientific, Wilmington, DE). Only samples with
an RNA integrity number (RIN) above 7 were used for
RT-PCR assays (Agilent, Santa Clara, CA). One μg of
total RNA was reverse transcribed (RT) using the Cloned
AMV First-Strand cDNA Synthesis Kit (Invitrogen, Grand
Island, NY). Commercially available RT-qPCR primers
(SABiosciences, Valencia, CA) were obtained for the
housekeeping gene, hydroxymethylbilane sythase (HMBS),
and seven inflammatory cytokines that included: IL-4,
IL-6, IL-8, IL-10, IL-17, TNF-α, and IFN-γ. Each reac-
tion contained 2 μL of cDNA, 1 μM of each primer,
and 5 μL of Fast-SYBR Green Master Mix (Applied
Biosystems, Carlsbad, CA). Cycling conditions were:
1 cycle at 95°C for 10 min followed by 45 cycles of
95°C for 15 s, 60°C for 1 min, and 72°C for 30 s. All
samples were run in duplicate for both the target and
housekeeping genes. The housekeeping gene was used
for normalization. Pooled RNA from control subjects
was included with each batch of RT-PCR reaction and
served as a reference. This pooled RNA also served as
a calibration point across different batches of PCR
runs. Transcript abundance was calculated by the
delta-delta threshold cycle (ΔΔCt) method [23]. Add-
itional quality control measures included initial valid-
ation of qPCR efficiency for all target genes and the
housekeeping gene. Standard curves were generated
using dilutions series of standards for target or house-
keeping genes and the PCR efficiency was calculated
using the method of Pfaffl et al. [24]. The amplifica-
tion efficiency of the target genes and housekeeping
standard were comparable.
Statistical analysis. Participant characteristics were
compared using student’s t-test or a chi squared test.
Median concentrations of plasma endotoxin and inflam-
matory markers were compared between controls and
cases by the Mann–Whitney U test as this data was
highly skewed and not normally distributed. As a result,
we used nonparametric approaches (Mann–Whitney U
tests) which do not assume normality.
Plasma endotoxin concentrations in controls were used
to determine upper and lower 50% cut points. Upper and
lower halves of plasma endotoxin concentrations were
compared between cases and controls using unconditional
logistic regression and odds ratio. Plasma cytokines, tissue
cytokines, BMI, physical activity, smoking status and daily
Table 1 General characteristics of study population
Characteristics Case
(n=138)
Control
(n=342)
p
Age (years), mean (se) 57.0 (0.6) 55.2 (0.4) 0.01
Sex, n (%)
Male 72 (55) 142 (47) 0.12
Race, n (%)
White 121 (88) 296 (89) 0.73
Black 16 (12) 35 (11)
BMI, n (%) 0.03
Normal 43 (32) 147 (44)
Overweight 61 (45) 113 (34)
Obese 32 (24) 74 (22)
Waist/Hip ratio (mean (se)) 0.934 (0.007) 0.907 (0.004) 0.001
Calories (kcal/day), mean (se) 1986 (65) 1993 (47) 0.92
Smoking Status, n (%) 0.62
Current 11 (8) 26 (9)
Former 41 (32) 109 (36)
Never 78 (60) 166 (55)
Physical activity 2263 (215) 2565 (159) 0.28
(MET minutes per day), mean
(se)
Fat intake (grams/day), mean
(se)
75.8 (2.8) 77.0 (1.9) 0.71
Number of adenomas, mean
(se)
1.8 (0.1)
Size of adenomas (mm), mean
(se)
5.7 (0.4)
New adenoma histology
Tubular, n (%) 100 (95)
Villous, n (%) 5 (5)
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added to a logistic regression model with case status as
the response and upper or lower halves of endotoxin
concentrations as the predictor. If the odds ratios (OR) for
the concentrations of endotoxin changed by at least 10%
after the inclusion of the new variable in the model, then
that variable was considered to be a potential confounder.
After all such potential confounders were identified,
they were all entered into the model along with the
concentrations of endotoxin, and a backwards stepwise
procedure was performed with endotoxin being forced
into the model. Ultimately, we identified all tissue
cytokines and dietary fat as confounders and ran the
final logistic regression model with adjustment for
these variables.
Associations between endotoxin concentrations and
adenoma size, number, grade and location were also
assessed by Mann–Whitney U test. The relationship be-
tween each plasma or rectal mucosal cytokine and endo-
toxin concentrations was also evaluated by multivariate
logistic regression while adjusting for the levels of other
plasma or rectal mucosal cytokines. P-values less than
0.05 were considered statistically significant while P-
values greater than 0.05 but less than 0.10 were
considered a trend toward significance. P-values were
adjusted for multiple comparisons via False Discovery
Rate [25].
Results
We evaluated concentrations of plasma endotoxin and
local and systemic inflammatory cytokines from 138
cases and 324 controls. The characteristics of cases and
controls are shown in Table 1. Subjects were evenly
distributed between males and females and were mostly
Caucasians. Compared to controls, cases were slightly
older and more likely to be overweight and obese. All
adenomas were discovered in the colon, and only 5
subjects had adenomas with a villous component. We
analyzed the data using only tubular adenomas, but
results were largely unchanged from when we analyzed
tubular and villous adenomas together. Thus, we present
the data for all adenomas.
The median levels of endotoxin concentrations for
cases was 4.1 (1.8-26.8 EU/mL) and for controls 3.8
(1.8-26.4 EU/mL). Plasma endotoxin concentrations
were divided into higher and lower concentrations
based on the cut points in controls. Compared to
subjects in low plasma endotoxin concentrations, those
with higher concentrations were significantly more
likely to have adenomas when adjusted for rectal muco-
sal cytokines and dietary fat (OR=1.4, CI 95% 1.0–2.1)
(Table 2).
We also assessed whether concentrations of plasma
endotoxin were associated with adenoma characteristics.The average number of adenomas was 1.8 per person
(range 1–9). The adenoma size distribution was as
follows: small adenoma, 1–5 mm, 66%; medium aden-
oma, 6–10 mm, 25%; large adenoma, >10 mm, 9%
(Table 3). Endotoxin concentration was significantly
higher in those with villous adenomas than tubular
adenomas (p<0.05) (Table 3). However, there were no
associations between adenoma size or number and
endotoxin concentrations.
Median plasma or rectal mucosal cytokine levels were
not different between cases and controls, with the excep-
tion of plasma TNF-α levels which showed a trend
toward being higher in those with adenomas than those
without adenomas (p=0.06) (Table 4, Table 5). We
compared plasma and rectal mucosal cytokines between
cases with one versus multiple adenomas, cases with at
least one adenoma of at least 1 cm in size versus all
adenomas less than 1 cm in size, and cases with at least
one adenoma with villous component versus all
Table 3 Endotoxin concentration analysis by adenoma
characteristics
n Median (25th, 75th) p
Adenoma size
1-5 mm 90 4.11 (2.21, 5.21) 0.44
6-10 mm 34 4.06 (2.81, 5.38)
>10 mm 13 4.95 (3.44, 5.61)
Adenoma number
1-2 109 4.13 (2.54, 5.27) 0.60
3+ 29 4.22 (2.08, 5.69)
Adenoma grade
Tubular 100 4.11 (2.19, 5.30) 0.05
Villous* 5 5.41 (4.86, 5.61)
Adenoma location
Proximal 50 4.14 (2.84, 5.35) 0.90
Distal 88 4.13 (2.19, 5.36)
*Any adenomas containing villous components were classified as villous.
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Mann–Whitney U test. In subjects with multiple aden-
omas as compared to those with only one adenoma, only
median mucosal IL-12 level was significantly higher
(1.09 vs. 0.65, p=0.04). In subjects with villous adenomas,
only median plasma IFN-γ was significantly lower than in
those with only tubular adenomas (0 vs. 1.64 pg/mL,
p=0.02). None of the other comparisons for number of ad-
enomas or adenoma type and plasma or rectal mucosal
cytokines were statistically significant (results not shown).
In addition, we examined the relationship between
plasma endotoxin concentrations and a panel of plasma
or rectal mucosal cytokines using multivariate logistic
regression. We found that those in the upper half of
endotoxin concentrations were significantly more likely
to have higher plasma IL-12 as compared to those in the
lower half of endotoxin concentrations (OR=1.5, CI 95%
1.0-2.2) (Additional file 1: Table S1). Similarly, those in
the upper half of endotoxin concentrations were signifi-
cantly more likely to have higher mucosal IL-12
(OR=1.9, CI 95% 1.0–3.7) and mucosal IL-17 (OR=2.2,
CI 95% 1.0–4.6) than those in the lower half of the
endotoxin concentrations (Additional file 1: Table S1).
No statistically significant results were found for the
remaining cytokines.
Discussion
This study evaluated the relationship between endotoxemia
and colorectal adenomas and their association with
systemic and mucosal cytokines. We found an association
between high endotoxin concentrations and adenomas.
Compared to those with low endotoxin concentrations,
those with higher endotoxin concentrations were more
likely to be cases. We also observed a positive associ-
ation between villous adenomas and high endotoxin
concentrations. Only plasma TNF-α levels showed a
trend toward being higher in adenoma cases than
controls (p=0.06). None of the other plasma or rectal
mucosal cytokine levels was significantly different be-
tween cases and controls. In multivariate analysis,
higher concentrations of endotoxin predicted increased
plasma levels of IL-12 as well as rectal mucosal gene
expression levels of IL-12 and mucosal IL-17. Increased
mucosal gene expression level of IL-12 was also
associated with multiple adenomas.Table 2 Association between plasma endotoxin
concentrations and presence of adenomas
Plasma Endotoxin Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)*
Lower Half (0–3.76 EU/mL) 1.0 (Ref) 1.0 (Ref)
Upper Half (3.80-26.39 EU/mL) 1.4 (1.0, 2.1) 1.4 (1.0, 2.1)
OR odds ratio, CI confidence interval.
*adjusted for rectal mucosal cytokines and daily dietary fat.We found that subjects with adenomas were more
likely to have higher endotoxin concentrations, espe-
cially those with villous adenomas. High dietary fat in-
take has been shown to increase endotoxemia [26], and
in our study, positive relationship between adenoma
status and endotoxemia was maintained even after
adjusting for rectal mucosal cytokines and dietary fat.
Limited studies have evaluated the association between
endotoxins and colorectal adenomas. A recent report by
Lee et al. demonstrated that endotoxin concentrations
were higher in individuals with polyps, especially dys-
plastic adenomas. Our results are consistent with their
findings [27]. To our knowledge, these are the first stud-
ies to show that higher endotoxin concentrations are
associated with adenoma risk in humans. While Lee
et al. did not evaluate any mechanisms that could
explain the endotoxin relationship to adenomas, we
propose that bacterial dysbiosis in favor of over-
abundance of gram-negative bacteria in individuals with
adenomas could lead to increased endotoxin release, and
thereby contribute to elevated production of inflamma-
tory cytokines. This, in turn, could promote leakiness of
the intestinal mucosal barrier and translocation of endo-
toxin into the blood stream. A recent study showed that
intraluminal administration of LPS in the colon resulted
in altered local cytokine production suggesting that
elevated LPS in the colon is able to cause intestinal in-
flammation [28].
Chronic inflammation is a risk factor for colorectal
cancer. We have previously shown that elevated levels of
plasma IL-6 and TNF-α are associated with increased
risk of adenomas [21]. In this study, we found a border-
line association between plasma TNF-α levels and colo-
rectal adenomas. Evaluation of the relationship between
Table 4 Comparison of plasma concentration of endotoxin and plasma cytokine levels among cases and controls
Plasma levels, units Case (n=138) Control (n=342) p Adjusted
(median (min, max)) (median (min, max)) p*
TNF-α (pg/mL) 4.8 (1.3, 276.6) 4.3 (0, 268.3) 0.008 0.06
IL-4 (pg/mL) 4.3 (0, 916.5) 2.6 (0, 5459.2) 0.07 0.19
IL-6 (pg/mL) 4.1 (0, 1099.1) 4.0 (0, 911.1) 0.70 0.80
IL-8 (pg/mL) 3.0 (0, 131.2) 2.7 (0, 291.1) 0.07 0.19
IL-10 (pg/mL) 8.5 (0, 1644.7) 7.4 (0, 1308.8) 0.60 0.80
IL-12 (pg/mL) 0.5 (0, 716.1) 0.5 (0, 1106.3) 0.82 0.82
IFN-γ (pg/mL) 1.4 (0, 924.8) 1.5 (0, 390.0) 0.57 0.80
TNF tumor necrosis factor, IL interleukin, IFN Interferon.
* adjusted for multiple comparisons via False Discovery Rate.
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that plasma IL-12 levels, and rectal mucosal levels of
IL-12 and IL-17 were likely to be elevated with
increased endotoxin concentrations. This observation
for IL-12 is consistent with published literature demon-
strating imbalance in Th1 cytokine network in colorec-
tal carcinogenesis [29,30]. IL-17 is a pro-inflammatory
cytokine that could promote tumorigenesis and tumor
progression [31,32]. Our observations support an associ-
ation between plasma endotoxin concentrations and
markers of systemic and mucosal inflammation.
When we analyzed rectal mucosal and plasma cytokines
in relation to adenoma characteristics, we found that
those with villous adenomas were more likely to have
lower plasma IFN-γ. IFN-γ is mainly induced by IL-12.
Elevated levels of IL-12 have been reported in adenomas
while decreased levels have been noted in CRC [29,30]. As
villous adenomas are more likely to be dysplastic than
tubular adenomas and closer in progression to CRC, it is
possible that changes in cellular immunity such as altered
levels of immune markers, IL-12 and IFN-γ, couldTable 5 Comparison of tissue cytokine levels among
cases and controls
Tissue
levels, *
Case (n=111) Control (n=278) p Adjusted
(median (min,
max))
(median (min,
max))
p**
TNF-α 0.8 (0.03, 18.6) 0.8 (0, 18.2) 0.92 0.92
IL-4 0.5 (0, 16.0) 0.4 (0, 14.4) 0.08 0.29
IL-6 1.0 (0.06, 41.2) 1.1 (0.1, 39.1) 0.77 0.88
IL-8 0.5 (0, 24.8) 0.5 (0, 32.4) 0.44 0.59
IL-10 0.4 (0, 115.1) 0.6 (0, 72.9) 0.05 0.29
IL-12 0.7 (0.04, 24.3) 0.8 (0.01, 16.3) 0.34 0.54
IL-17 0.7 (0, 12.4) 0.9 (0, 15.1) 0.11 0.29
IFN-γ 0.8 (0.06, 56.6) 0.7 (0.02, 24.8) 0.34 0.54
TNF tumor necrosis factor, IL interleukin, IFN Interferon.
*Relative gene expression to HMBS and normalized to pooled RNA of controls.
** adjusted for multiple comparisons via False Discovery Rate.contribute to cancer development. Our results demon-
strate that rectal mucosal inflammatory cytokines are posi-
tively associated with plasma endotoxin concentrations,
particularly for adenoma cases. These results are consis-
tent with prior literature showing a correlation between
endotoxemia and inflammatory cytokines and oxidative
stress markers, and suggest a role of microbiota in medi-
ation of inflammation and adenoma formation via endo-
toxin production [14,33].
Given that the gut is colonized by complex bacterial
communities, we acknowledge that elevated endotoxin
concentrations alone may be insufficient to promote in-
flammation and adenomas. It is likely that other bacteria
or bacterial products may be involved. For, example,
Streptococcus gallolyticus (formerly S. bovis), a gram-
positive bacteria, has been associated with colorectal ad-
enomas and cancer [12]. S. gallolyticus is thought to pro-
mote increased production of inflammatory cytokines
and development of colorectal tumors via the release of
cell wall antigens [34]. However, our previous studies,
demonstrating an increased abundance of LPS-rich
Proteobacteria, particularly Escherichia coli, in associ-
ation with adenomatous states [13,14] provide a good ra-
tionale for evaluating bacterial endotoxins, inflammation
and adenomas.
In this study, we used mucosal biopsies obtained from
the rectum while the adenomas were found in the colon.
The rectum has been routinely sampled in human stud-
ies to assess biomarkers of colorectal adenomas and can-
cer. This is based on the idea of a “field effect” whereby
events occurring in the rectum are reflective of events
going on elsewhere in the colon [35-39]. Ponz de Leon
et al. examined mucosal proliferation in different tracts
of the large bowel in subjects with colorectal polyps or
cancer and normal controls [40]. They found no signifi-
cant differences in cell proliferation between mucosal
samples taken at various distances from the colorectal
cancer margin suggesting that hyper-proliferation of the
entire colonic mucosa was common in patients with
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established that decreased apoptosis is a risk factor for
adenomas, and lower rates of apoptosis can be detected
from normal rectal mucosa distant from adenomatous
tissue [36]. This field effect has also been observed with
bacterial composition. Momozawa et al. examined seven
sites in the gut and noted that there were no significant
quantitative or qualitative differences in bacteria from
ileum to rectum, suggesting that the majority of bacteria
would be similar throughout the large intestine [41].
These studies support that rectal mucosal biopsies could
be a good surrogate for biopsies adjacent to adenomas.
We did not have comprehensive medical histories of
the subjects. While endotoxin transfer to the blood-
stream could be caused by other factors such as tissue
damage, infection and other medical conditions that
may induce systemic inflammation, all the subjects in
our study were ambulatory and healthy enough to
undergo outpatient screening colonoscopies. Although,
we did not have detailed past infection histories, one of
the inclusion criteria was that subjects had not taken
antibiotics within 12 weeks prior to colonoscopy, thus,
ruling out recent bacterial infections contributing to
inflammation.
A limitation of our study is that we used a commercially
available endpoint chromogenic LAL test with detection
level as its low as 0.1EU/ml. We chose this method be-
cause of its ability to quantitate plasma endotoxin as well
as low overall equipment cost. Even though we controlled
for protein inhibition of the LAL endotoxin assay, it is
possible that there were still components that could inter-
fere with the reaction and potentially obscure the distinc-
tion between cases and controls. However, our results are
comparable with other studies that evaluated presence of
plasma endotoxin in healthy individuals [42-44]. Lastly,
we did not measure endotoxin concentrations in the mu-
cosa, which could be more relevant to adenoma forma-
tion. We also recognize that with the cross-sectional
nature of our study, we cannot establish a causal relation-
ship between endotoxin, inflammation and colorectal ad-
enomas, and that studies in animal models are needed to
assess potential mechanisms. This study has several
strengths which include a large sample size, detailed
exposure information, and evaluation of both local and
systemic markers of inflammation.
Conclusion
To the best of our knowledge, this is one of the first
studies to evaluate the association of plasma endotoxin
and inflammation in relation to the risk of colorectal
adenomas. We found a positive association between
plasma endotoxin concentrations and adenomas as well
as several measures of rectal mucosal inflammation. In
particular, higher levels of endotoxin predicted increasedplasma and mucosal IL-12 and mucosal IL-17. Those
with villous adenoma histology were more likely to have
higher endotoxin but lower plasma IFN-γ as compared
to those with tubular histology. Thus, our study suggests
that bacterial endotoxins are associated with increased
levels of plasma and rectal mucosal cytokines, especially
in subjects with adenomas.
Additional file
Additional file 1: Table S1. Odds ratios (95% CI) for elevated levels of
cytokines given elevated endotoxin concentrations.
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